BioMarin Pharmaceutical, Inc. (BMRN)
59.94
-0.37
(-0.61%)
USD |
NASDAQ |
Feb 12, 16:00
59.98
+0.04
(+0.06%)
After-Hours: 20:00
BioMarin Pharmaceutical Cash from Investing (Quarterly) : -330.96M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amicus Therapeutics, Inc. | -1.299M |
| Gilead Sciences, Inc. | -1.835B |
| Merck & Co., Inc. | -- |
| AbbVie, Inc. | -- |
| Biogen, Inc. | -1.232B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 368.68M |
| Cash from Financing (Quarterly) | -2.169M |
| Free Cash Flow | 825.79M |
| Free Cash Flow Per Share (Quarterly) | 1.744 |
| Free Cash Flow to Equity (Quarterly) | 335.63M |
| Free Cash Flow to Firm (Quarterly) | 337.95M |
| Free Cash Flow Yield | 7.05% |